[1] 廖栩鹤, 王荣福.18F-FDG PET/CT在乳腺癌原发病灶诊断及分期的应用价值[J].中华临床医师杂志(电子版), 2010, 4(10):1946-1949. [2] 任军. 乳腺癌的分子靶向治疗[J]. 中国实用内科杂志, 2007, 27(24):1907-1910. [3] Suman P, Poehlmann TG, Prakash GJ, et al. Interleukin-11 increases invasiveness of JEG-3 choriocarcinoma cells by modulating STAT3 expression[J]. J Reprod Immunol, 2009, 82(1):1-11. [4] Markert UR, Morales-Prieto DM, Fitzgerald JS. Understanding the link between the IL-6 cytokine family and pregnancy: implications for future therapeutics[J]. Expert Rev Clin Immunol, 2011, 7(5):603-609. [5] Suchorska WM, Dams-Kozlowska H, Kazimierczak U, et al. Hyper-interleukin-11 novel designer molecular adjuvant targeting gp130 for whole cell cancer vaccines[J]. Expert Opin Biol Ther, 2011, 11(12):1555-1567. [6] Cardó-Vila M, Zurita AJ, Giordano RJ, et al.A ligand peptide motif selected from a cancer patient is a receptor-interacting site within human interleukin-11[J].PLoS One, 2008, 3(10):e3452. [7] Du X, Williams DA. Interleukin-11: review of molecular, cell biology, and clinical use[J]. Blood, 1997, 89(13):3897-3908. [8] Nakayama T, Yoshizaki A, Izumida S, et al.Expression of interleukin-1l(ILl1)and ILl1 receptor a in human gastric carcinoma and ILll upregulates the invasive activity of human gastric carcinoma cells[J].Int J Oncol, 2007, 30(4):829. [9] 陈心, 罗素兰, 张本, 等.多肽固相合成的研究进展[J].生物技术, 2006, 16(1):81-82. [10]Grillo-Bosch D, Rabanal F, Giralt E.Improved Fmoc-based Solid-phase synthesis of homologous peptide fragments of human and mouse prion proteins[J].J Pept Sci, 2011, 17(1) :32-38. |